Verrica Pharmaceuticals reports Q4 EPS (53c), consensus (53c)

Reports Q4 revenue $1.866M, consensus $910k. “We continued to make considerable progress with the launch of YCANTH during our first full quarter of commercial operations,” said Ted White, Verrica’s President and Chief Executive Officer. “With a growing confidence and adoption in our prescriber base, over 200 million commercial and Medicaid lives now covered, a permanent J-code that will be published on April 1, and a significant decrease in the availability and supply of improperly compounded cantharidin, we continue to execute on the core pillars of our YCANTH launch strategy. With these fundamentals in place, we look forward to accelerating the trajectory of the YCANTH launch in 2024.”